Stock Update (NASDAQ:BPMC): Blueprint Medicines Corp and PatientCrossroads Launch Registry for Mastocytosis Patients to Increase Understanding of Disease and Speed Therapeutic Development

Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, and PatientCrossroads, a pioneer in spearheading the adoption of patient-entered disease registries, today announced the launch of Mast Cell Connect, a patient registry to advance the understanding of mastocytosis and help speed the development of new therapies. Blueprint Medicines, which is developing a treatment for patients with systemic mastocytosis, is sponsoring the registry. PatientCrossroads’ robust platform will be used to host and manage the registry, including patient privacy, data collection and access.

“We are proud to support the creation of Mast Cell Connect, the first-ever open-model registry to capture the perspective of patients living with mastocytosis,” said Jeffrey Albers, Chief Executive Officer of Blueprint Medicines. “This new resource will bring Blueprint Medicines, researchers and the broader medical community greater insights about the needs of people living with the disease and enable patients to sign up for updates about clinical trials and other important developments.”

Participation in Mast Cell Connect is voluntary and open to those diagnosed with mastocytosis, a rare disease in which immune cells known as mast cells abnormally build up in the skin, bone marrow and other parts of the body. The registry will include patients with all forms of the disease, including systemic mastocytosis, cutaneous mastocytosis and their subtypes. By participating in Mast Cell Connect, patients will be able to view de-identified perspectives from other patients living with the disease, and may consent to be notified of clinical trials and other research studies. Recruitment efforts for the registry will initially be focused in the United States, but Mast Cell Connect is open to patients from anywhere in the world.

“We have observed over the years how patient registries have made an impact on advancing clinical development for other rare diseases, like Duchenne Muscular Dystrophy and Friedreich’s ataxia. These databases of detailed medical information have proven to be a valuable tool in better understanding such disease areas,” said Valerie Slee, RN, BSN, Chair of the Board of Directors for The Mastocytosis Society (TMS), the U.S.-based patient advocacy organization for the disease. “Mast Cell Connect will galvanize patients to share information about their experiences with mastocytosis with the greater medical community.”

“PatientCrossroads was founded on the philosophy that making patient registries available to disease communities and sharing this data via an open model will facilitate a new level of cross-collaboration, and ultimately, the development of new therapies,” said Kyle Brown, Chief Executive Officer and Founder of PatientCrossroads. “We believe that Mast Cell Connect will contribute to better care for people with mastocytosis by systematically documenting the impact and natural history of this rare disease and increasing participation in clinical studies.”

In addition to launching Mast Cell Connect, Blueprint Medicines today launched a disease awareness website called “Together with Systemic Mastocytosis.” The goal of this website is to inform, empower and engage patients with systemic mastocytosis and their caregivers. (Original Source)

Shares of Blueprint Medicines Corp. closed yesterday at $23.16, up $1.02 or 4.61%. BPMC has a 1-year high of $37.17 and a 1-year low of $18. The stock’s 50-day moving average is $21.54 and its 200-day moving average is $26.45.

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation.



Stay Ahead of Everyone Else

Get The Latest Stock News Alerts